Gilead Sciences, Inc. is an American biopharmaceutical company headquartered in Foster City, California, that focuses on researching and developing antiviral drugs used in the treatment of HIV/AIDS, hepatitis B, hepatitis C, influenza, and COVID-19, including ledipasvir/sofosbuvir and sofosbuvir.
Company profile
Ticker
GILD
Exchange
Website
CEO
Daniel O'Day
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
GILEAD SCIENCES INC
SEC CIK
Corporate docs
Subsidiaries
Asegua Therapeutics LLC • Forty Seven, Inc. • Forty Seven Holdings, LLC • Gilead Alberta, LLC • Gilead Apollo, LLC • Gilead Biopharmaceutics US LLC • Gilead Calistoga, LLC • Gilead Connecticut, Inc. • Gilead Holdings, LLC • Gilead Pharmasset LLC ...
IRS number
943047598
GILD stock data
Latest filings (excl ownership)
8-K
Amendments to Articles of Incorporation or Bylaws
9 May 24
10-Q
2024 Q1
Quarterly report
8 May 24
8-K
Gilead Sciences Announces First Quarter 2024 Financial Results
25 Apr 24
ARS
2023 FY
Annual report to shareholders
28 Mar 24
DEFA14A
Additional proxy soliciting materials
28 Mar 24
DEF 14A
Definitive proxy
28 Mar 24
8-K
Gilead Sciences Announces Completion of Acquisition of Cymabay
22 Mar 24
SC TO-T/A
Third party tender offer statement (amended)
22 Mar 24
SC TO-T/A
Third party tender offer statement (amended)
20 Mar 24
PRE 14A
Preliminary proxy
18 Mar 24
Transcripts
GILD
Earnings call transcript
2024 Q1
25 Apr 24
GILD
Earnings call transcript
2023 Q4
6 Feb 24
GILD
Earnings call transcript
2023 Q3
7 Nov 23
GILD
Earnings call transcript
2023 Q2
3 Aug 23
GILD
Earnings call transcript
2023 Q2
3 Aug 23
GILD
Earnings call transcript
2023 Q1
27 Apr 23
GILD
Earnings call transcript
2022 Q4
2 Feb 23
GILD
Earnings call transcript
2022 Q3
28 Oct 22
GILD
Earnings call transcript
2022 Q2
2 Aug 22
GILD
Earnings call transcript
2022 Q1
29 Apr 22
Latest ownership filings
Financial summary
Quarter (USD) | Mar 24 | Dec 23 | Sep 23 | Jun 23 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 23 | Dec 22 | Dec 21 | Dec 20 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 4.72 bn | 4.72 bn | 4.72 bn | 4.72 bn | 4.72 bn | 4.72 bn |
Cash burn (monthly) | 455.67 mm | 18.17 mm | 1.50 bn | (no burn) | (no burn) | (no burn) |
Cash used (since last report) | 1.02 bn | 40.73 mm | 3.35 bn | n/a | n/a | n/a |
Cash remaining | 3.70 bn | 4.68 bn | 1.37 bn | n/a | n/a | n/a |
Runway (months of cash) | 8.1 | 257.5 | 0.9 | n/a | n/a | n/a |
Institutional ownership, Q1 2024
80.5% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 1615 |
Opened positions | 336 |
Closed positions | 211 |
Increased positions | 509 |
Reduced positions | 590 |
13F shares | Current |
---|---|
Total value | 69.22 tn |
Total shares | 1.00 bn |
Total puts | 7.95 mm |
Total calls | 8.49 mm |
Total put/call ratio | 0.9 |
Largest owners | Shares | Value |
---|---|---|
BLK Blackrock | 122.53 mm | $8.98 tn |
Vanguard | 114.73 mm | $8.40 tn |
Capital World Investors | 84.50 mm | $6.19 tn |
Capital Research Global Investors | 61.25 mm | $4.49 tn |
STT State Street | 57.70 mm | $4.23 tn |
Dodge & Cox | 33.17 mm | $2.43 tn |
Geode Capital Management | 26.35 mm | $1.93 tn |
Wellington Management | 20.57 mm | $1.51 tn |
MS Morgan Stanley | 18.01 mm | $1.32 tn |
FMR | 17.59 mm | $1.29 tn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
8 May 24 | Kramer Kelly A. | NQSO Common Stock | Grant | Acquire A | No | No | 64.92 | 12,648 | 821.11 k | 12,648 |
8 May 24 | Kramer Kelly A. | RSU Common Stock | Grant | Acquire A | No | No | 0 | 2,310 | 0.00 | 17,594 |
8 May 24 | Horning Sandra | NQSO Common Stock | Grant | Acquire A | No | No | 64.92 | 12,648 | 821.11 k | 12,648 |
8 May 24 | Horning Sandra | RSU Common Stock | Grant | Acquire A | No | No | 0 | 2,310 | 0.00 | 7,801 |
8 May 24 | Bluestone Jeffrey | NQSO Common Stock | Grant | Acquire A | No | No | 64.92 | 12,648 | 821.11 k | 12,648 |
8 May 24 | Bluestone Jeffrey | RSU Common Stock | Grant | Acquire A | No | No | 0 | 2,310 | 0.00 | 4,197 |
8 May 24 | Manwani Harish | Common Stock | Payment of exercise | Dispose F | No | No | 64.92 | 451 | 29.28 k | 12,873 |
8 May 24 | Manwani Harish | Common Stock | Grant | Acquire A | No | No | 0 | 2,310 | 0.00 | 13,324 |
8 May 24 | Manwani Harish | NQSO Common Stock | Grant | Acquire A | No | No | 64.92 | 12,648 | 821.11 k | 12,648 |
8 May 24 | Welters Anthony | Common Stock | Grant | Acquire A | No | No | 0 | 2,310 | 0.00 | 10,232 |
News
Gilead Sciences' Phase 2B MYR204 Open-label Study Showed Bulevirtide Plus Pegylated Interferon Alfa-2A For Compensated Chronic Hepatitis Delta Virus Demonstrated Bulevirtide Combo Achieved Undetectable HDV RNA At Week 24 After The End Of Treatment
6 Jun 24
$100 Invested In This Stock 20 Years Ago Would Be Worth $800 Today
5 Jun 24
Gilead's Seladelpar Shows Continued And Reliable Long-Term Effectiveness And Safety In Treating Primary Biliary Cholangitis
5 Jun 24
National Institutes of Health Kickstarts Gilead Sponsored Trials For Twice-Yearly HIV Prevention Injection
4 Jun 24
Gilead Sciences Reaches Agreement In Principle To Settle Federal TDF Litigation For Up To $40M
4 Jun 24
Press releases
Gilead Announces New England Journal of Medicine Publication of Data that Demonstrate Bulevirtide with PegIFN Achieved Post-Treatment Undetectable HDV RNA
6 Jun 24
Gilead's Seladelpar Demonstrated a Sustained and Consistent Long-Term Efficacy and Safety Profile in Primary Biliary Cholangitis
5 Jun 24
Kite's Tecartus® Demonstrates Sustained Overall Survival in Adult Patients With Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia
3 Jun 24
Encouraging New Data Presented on Kite's Yescarta® for Relapsed/Refractory Central Nervous System Lymphoma
3 Jun 24
Gilead and Arcus Announce Etrumadenant Plus Zimberelimab Regimen Significantly Reduced the Risk of Death in Third-line Metastatic Colorectal Cancer
2 Jun 24